Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Semperit, Pierer Mobility (27/12/2022)

01.01.2023

Marinomed Biotech: Marinomed Biotech AG, listed on the Vienna Stock Exchange (VSE:MARI), announced that the United States Patent and Trademark Office has granted the patent US11510859 covering the Marinosolv technology and its solubility enhancing properties. Specifically, the patent protects Marinosolv as a method for improving the aqueous solubility of drugs that are hardly soluble in aqueous formulations. By increasing solubility, the Marinosolv technology can significantly improve existing and development-stage drugs for the treatment of a multitude of diseases. Andreas Grassauer, CEO of Marinomed, says: "The granting of the US patent proves once again the outstanding innovative strength of Marinomed and our Marinosolv technology. We have thus laid the foundations in all relevant markets to use our technology to increase the solubility and bioavailability of poorly soluble active ingredients and enable the development of new therapeutics. This holds true for the technology and our Marinosolv-derived pipeline, including our two drug candidates Budesolv and Tacrosolv, as well as for our Solv4U technology partnerships. The comprehensive patent protection in Europe, China and the U.S. is a strong asset to attract additional partners to our technology and will support our growth efforts."
Marinomed Biotech: weekly performance: -1.05%

Semperit: Herbert Ortner resigns from his position as Chairman of the Supervisory Board of Semperit AG Holding and leaves the Supervisory Board. The agendas of the Chairman of the Supervisory Board will be taken over on an interim basis by the Deputy Chairman of the Supervisory Board, Stefan Fida, until the next Annual General Meeting on April 25, 2023. At the 134th Annual General Meeting in April 2023, the Supervisory Board of Semperit AG Holding will propose Cord Prinzhorn for election to the Supervisory Board, who is designated to assume the chairmanship in the future.
Semperit: weekly performance: -2.36%

Pierer Mobility: Pierer Mobility, with its brands KTM, Gasgas aor Husqvarna, increases the revenue forecast for the financial year 2022 to a growth of 15 to 20 percent compared to the previous year (previously forecasted 10 to 15 per cent).  The forecasts for the EBIT margin of 8 to 10 percent and an EBITDA margin between 15 and 17 per cent are confirmed. Due to the expected record result for the financial year 2022, the Management Board, in coordination with the main shareholder Pierer Bajaj AG, will propose a dividend of at least EUR 2,-- per dividend-bearing share to the Supervisory Board and the Annual General Meeting, which corresponds at least to a doubling compared to the previous year.
Pierer Mobility: weekly performance: 10.62%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (27/12/2022)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Semperit, Pierer Mobility (27/12/2022)


01.01.2023, 2801 Zeichen



Marinomed Biotech: Marinomed Biotech AG, listed on the Vienna Stock Exchange (VSE:MARI), announced that the United States Patent and Trademark Office has granted the patent US11510859 covering the Marinosolv technology and its solubility enhancing properties. Specifically, the patent protects Marinosolv as a method for improving the aqueous solubility of drugs that are hardly soluble in aqueous formulations. By increasing solubility, the Marinosolv technology can significantly improve existing and development-stage drugs for the treatment of a multitude of diseases. Andreas Grassauer, CEO of Marinomed, says: "The granting of the US patent proves once again the outstanding innovative strength of Marinomed and our Marinosolv technology. We have thus laid the foundations in all relevant markets to use our technology to increase the solubility and bioavailability of poorly soluble active ingredients and enable the development of new therapeutics. This holds true for the technology and our Marinosolv-derived pipeline, including our two drug candidates Budesolv and Tacrosolv, as well as for our Solv4U technology partnerships. The comprehensive patent protection in Europe, China and the U.S. is a strong asset to attract additional partners to our technology and will support our growth efforts."
Marinomed Biotech: weekly performance: -1.05%

Semperit: Herbert Ortner resigns from his position as Chairman of the Supervisory Board of Semperit AG Holding and leaves the Supervisory Board. The agendas of the Chairman of the Supervisory Board will be taken over on an interim basis by the Deputy Chairman of the Supervisory Board, Stefan Fida, until the next Annual General Meeting on April 25, 2023. At the 134th Annual General Meeting in April 2023, the Supervisory Board of Semperit AG Holding will propose Cord Prinzhorn for election to the Supervisory Board, who is designated to assume the chairmanship in the future.
Semperit: weekly performance: -2.36%

Pierer Mobility: Pierer Mobility, with its brands KTM, Gasgas aor Husqvarna, increases the revenue forecast for the financial year 2022 to a growth of 15 to 20 percent compared to the previous year (previously forecasted 10 to 15 per cent).  The forecasts for the EBIT margin of 8 to 10 percent and an EBITDA margin between 15 and 17 per cent are confirmed. Due to the expected record result for the financial year 2022, the Management Board, in coordination with the main shareholder Pierer Bajaj AG, will propose a dividend of at least EUR 2,-- per dividend-bearing share to the Supervisory Board and the Annual General Meeting, which corresponds at least to a doubling compared to the previous year.
Pierer Mobility: weekly performance: 10.62%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (27/12/2022)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #639: KESt-Story bei Addiko,, Bawag stark, die 1900er-Anekdote und VIG vs. Commerzbank?




 

Bildnachweis

Aktien auf dem Radar:Polytec Group, Immofinanz, Marinomed Biotech, Austriacard Holdings AG, Flughafen Wien, Warimpex, AT&S, Strabag, Uniqa, Wienerberger, EVN, Erste Group, Österreichische Post, ams-Osram, Josef Manner & Comp. AG, Wiener Privatbank, Addiko Bank, Oberbank AG Stamm, BKS Bank Stamm, Agrana, Amag, CA Immo, Kapsch TrafficCom, OMV, Telekom Austria, VIG.


Random Partner

AT&S
Austria Technologie & Systemtechnik AG (AT&S) ist europäischer Marktführer und weltweit einer der führenden Hersteller von Leiterplatten und IC-Substraten. Mit 9.526 Mitarbeitern entwickelt und produziert AT&S an sechs Produktionsstandorten in Österreich, Indien, China und Korea und ist mit einem Vertriebsnetzwerk in Europa, Asien und Nordamerika präsent. (Stand 06/17)

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten